A study exploring the effect of puerarin on skeletal muscle atrophy in rats with streptozotocin-induced type 1 diabetes. The dataset likely contains measurements of muscle weight, size, strength, fiber type transformation, and gene expression markers from in vivo and in vitro experiments. It was authored by Lin Yin from the Chinese Academy of Medical Sciences & Peking Union Medical College and shared via Papers with Code.
Use Cases
- Analyzing the relationship between puerarin treatment and muscle weight/strength metrics.
- Investigating gene expression changes for atrophy markers like Atrogin-1 and Murf-1.
- Studying the transformation of skeletal muscle fiber types (I to II) under diabetic conditions.
- Modeling the Akt/mTOR and LC3/p62 signaling pathways in response to a therapeutic compound.
Strengths
- Includes both in vivo rat model and in vitro cell line (L6) data, allowing for cross-validation.
- Measures multiple physiological endpoints: muscle weight, cross-sectional area, strength, and gene expression.
- Open Access license facilitates reuse and analysis.
Limitations
- Row count and dataset size are unknown, limiting suitability assessment.
- Column-level documentation is absent; field semantics must be inferred from the description.
- The description states applicability to humans remains unknown, indicating a potential limitation in generalizability.
Provenance
- Source
- Papers with Code
- Collection Method
- Experimental study using male Sprague Dawley rats with induced diabetes and L6 skeletal muscle cells.